Dry Eye

Slit lamp evaluation can provide valuable information for treatment course.

This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

By taking a proactive approach to treatment, ophthalmologists can identify the “silent sufferers.”

Ophthalmologists end their discussion on the management of dry eye disease with other ocular comorbidities highlighting key takeaways and prospective advances in care and outcomes.

Experts offer clinical advice and when to refer patients to specialists and the importance of building a supportive care network for patients.

Ophthalmologists offer their clinical insights and best practices of procedural therapies for dry eye management prior to surgery.

Experts discuss how dry eye disease can impact the preparation and post-operative care of cataract or refractory surgery, highlighting key approaches to successfully managing these patients.

Experts discuss their experience managing patients with dry eye disease and glaucoma, highlighting how dry eye disease impacts the progression of glaucoma and key considerations for treatment.

Ophthalmologists provide insights into their diagnostic protocols for assessing dry eye.

Expert panelists discuss the co-occurrence of dry eye disease with other ocular comorbidities and highlight the frequently observed concurrent ocular conditions.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

Stephanie Marioneaux, MD, an ophthalmologist and cornea specialist, addresses the widespread issue of digital eye strain in honor of World Sight Day.

An expert weighs in on considerations involved in the choice between multifocal and light adjustable lenses.

An expert ophthalmologist presents patient cases from her practice, demonstrating how light adjustable lenses have achieved remarkable outcomes for those with diverse corneal topographies.

An ophthalmology specialist discusses factors to consider when choosing premium intraocular lenses and effectively communicating these choices to patients.

Educating patients about the importance of consistent care is key.

An expert underscores the importance of a comprehensive dry eye examination and offers insights on distinguishing it from neurotrophic keratitis.

An expert examines a case involving a young male patient interested in LASIK treatment but facing meibomian gland atrophy.

An expert discusses the key considerations for addressing dry eye in a patient who has undergone multiple ocular procedures.

An expert presents a case of dry eye in a patient who has undergone several eye surgeries and now requires cataract surgery.

Clinicians must screen, diagnose, and manage for effective treatment.

Mile Brujic, OD, FAAO, discusses the use of specialty lenses vs glasses in some patients, as well as approaches to managing the symptoms of dry eye disease.

Mile Brujic, OD, FAAO, presents a patient case of a 67-year-old woman with dry eye disease and a history of radial keratotomy (RK) surgery.

Mile Brujic, OD, FAAO, shares considerations from a patient case, highlighting diagnostic tools in dry eye disease as well as the ability of the patient to use medication.

Mile Brujic, OD, FAAO, presents the case of a 42-year-old female patient with dry eye disease who has discomfort using eyedrops.

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.

The study examines the effectiveness of PL9643 for the treatment of patients with dry eye disease.

According to the company, full enrollment anticipated by first week of September. The phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED.